This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
DARZALEX® (daratumumab) received approval from the FDA on June 27, 2019 for the treatment of
newly diagnosed multiple myeloma (NDMM) in combination with lenalidomide and dexamethasone (Rd)
in adult patients who are ineligible for autologous stem cell transplant (ASCT) based on the
MAIA trial.1,2
MAIA (NCT02252172) was a randomized, open-label, multicenter,
active-controlled, phase 3 study evaluating the safety and efficacy of DARZALEX® in combination
with Rd (DRd) vs Rd in patients with NDMM ineligible for ASCT.1,3
Key eligibility criteria3
Transplant-ineligible (TIE) NDMM
ECOG PS ≤2
CrCl ≥30 mL/min
Stratification factors3
ISS disease stage (I, II, or III)
Geographic region (North America vs other)
Age (<75 vs ≥75 years)
*On days when daratumumab was administered,
dexamethasone was administered to patients in the DRd
arm and served as the treatment dose of steroid for that
day as well as the required pre-infusion
medication. †For patients older than 75 years of age or
with BMI <18.5, dexamethasone was administered at a
dose of 20 mg QW.
Primary endpoint1,3
Progression-free survival (PFS) based on International Myeloma Working Group (IMWG) criteria
*The ITT population included all patients who underwent randomization. Post hoc analyses showed no significant differences between the two groups in the characteristics evaluated at baseline. †ECOG PS is scored on a scale from 0 to 5, with 0 indicating no symptoms and higher scores indicating increasing disability. ‡Two patients had a score of greater than 2 (one patient had a score of 3, and another patient had a score of 4). §The ISS disease stage, which is derived on the basis of the combination of serum β2-microglobulin and albumin levels, consists of three stages. Higher stages indicate more severe disease. ‖This category includes IgD, IgE, IgM, and biclonal. ¶Cytogenetic risk was based on fluorescence in situ hybridization or karyotype analysis; patients who had a high-risk cytogenetic profile had at least one high-risk abnormality (del17p, t[14;16], or t[4;14]).
Primary endpoint: progression-free survival1
After 28 months of follow-up:
MAIA demonstrated an improvement in PFS in the DRd arm compared with the Rd arm; the median PFS had not been reached in the DRd arm and was 31.9 months (95% CI, 28.9–NR) in the Rd arm (HR, 0.56; 95% CI, 0.43–0.73; P<0.0001), representing a 44% reduction in the risk of disease progression or death in patients treated with DRd1,3
DRd3 (n =368)
Rd3 (n=369)
30-month estimated PFS rate, % (95% CI)
70.6 (65.0-75.4)
55.6 (49.5-61.3)
PD or death at 28 months, n (%)
97 (26.4)
143 (38.8)
After 64.5 months of follow-up:
Median PFS was 61.9 months (95% CI, 54.8–NE) in the DRd arm and 34.4 months (95% CI, 29.6-39.2) in the Rd arm1
DRd5
Rd5
60-month estimated PFS rate, %
52.1
29.6
After 56 months of follow-up:
A 32% reduction in the risk of death was observed with DRd vs Rd, and median OS had not been reached for either arm1
DRd6
Rd6
60-month estimated PFS rate, % (95% CI)
66.3 (60.8-71.3)
53.1 (47.2-58.6)
After 89 months of follow-up:
Median OS was 90.3 months (95% CI, 80.8–NE) in the DRd arm and 64.1 months (95% CI, 56.0-70.8) in the Rd arm1
DRd7
Rd7
7-year estimated OS rate, % (95% CI)
53.1 (47.8–58.2)
39.3 (34.1–44.5)
After 28 months of follow-up:
The following analysis is not included in the Prescribing Information for DARZALEX®. This analysis was not adjusted for multiple comparisons, and no conclusions should be drawn.
After 64.5 months of follow-up:
After 28 months of follow-up:
The following analysis is not included in the Prescribing Information for DARZALEX®. This analysis was not adjusted for multiple comparisons, and no conclusions should be drawn.
After 64.5 months of follow-up:
These analyses are not included in the Prescribing Information for DARZALEX®. These analyses were conducted post hoc, and there are insufficient numbers of patients per subgroup to make definitive conclusions of efficacy among the subgroups.
Objective: This post hoc subgroup analysis describes the efficacy and safety by baseline frailty in MAIA at a median follow-up of 64.5 months
Methods:
Frailty assessed using the IFM simplified frailty score at baseline
Non-frail = score of 0/1
Frail = score of ≥2
IFM simplified frailty index9
Score assessment
Score
Age(years)
≤75
0
76–80
1
>80
2
CCI
≤1
0
>1
1
ECOG PS
0
0
1
1
≥2
2
Results:
Patient population
Overall, 737 patients included (DRd, n=368; Rd, n=369)
Median age of 73 years (range, 45-90)
A total of 341 (46%) patients were frail, 88.0% of whom were ≥70 years
Objective: Reports efficacy and safety data from age subgroups (<70 years, ≥70 to <75 years, and ≥80 years) with a median follow-up of 64.5 months
Results:
Demographic and baseline disease characteristics in the ITT population and by age subgroup13
A total of 737 patients (DRd, n=368; Rd, n=369) were randomized in MAIA. Baseline characteristics were well balanced between treatment arms5
Characteristic
ITT
<70 years
≥70 to <75 years
≥75 years
≥80 years
DRd (n=368)
Rd (n=369)
DRd (n=78)
Rd (n=77)
DRd (n=130)
Rd (n=131)
DRd (n=160)
Rd (n=161)
DRd (n=66)
Rd (n=71)
Median age, years (range)
73 (50-90)
74 (45-89)
68 (50-69)
68 (45-69)
72 (70-74)
72 (70-74)
78 (75-90)
79 (75-89)
82 (79-90)
82 (80-89)
ECOG PS score, n (%)*
0
127 (34.5)
123 (33.3)
34 (43.6)
28 (36.4)
42 (32.3)
48 (36.6)
51 (31.9)
47 (29.2)
21 (31.8)
18 (25.4)
1
178 (48.4)
187 (50.7)
31 (39.7)
37 (48.1)
69 (53.1)
67 (51.1)
78 (48.8)
83 (51.6)
32 (48.5)
37 (52.1)
≥2
63 (17.1)
59 (16.0)
13 (16.7)
12 (15.6)
19 (14.6)
16 (12.2)
31 (19.4)
31 (19.3)
13 (19.7)
16 (22.5)
ISS disease stage, n (%)†
I
98 (26.6)
103 (27.9)
31 (39.7)
25 (32.5)
34 (26.2)
41 (31.3)
33 (20.6)
37 (23.0)
13 (19.7)
13 (18.3)
II
163 (44.3)
156 (42.3)
21 (26.9)
32 (41.6)
67 (51.5)
54 (41.2)
75 (46.9)
70 (43.5)
27 (40.9)
28 (39.4)
III
107 (29.1)
110 (29.8)
26 (33.3)
20 (26.0)
29 (22.3)
36 (27.5)
52 (32.5)
54 (33.5)
26 (39.4)
30 (42.3)
Type of measurable disease, n (%)
IgG
225 (61.1)
231 (62.6)
44 (56.4)
45 (58.4)
79 (60.8)
82 (62.6)
102 (63.8)
104 (64.6)
41 (62.1)
41 (57.7)
IgA
65 (17.7)
66 (17.9)
13 (16.7)
18 (23.4)
26 (20.0)
21 (16.0)
26 (16.3)
27 (16.8)
13 (19.7)
10 (14.1)
Other‡
9 (2.4)
10 (2.7)
2 (2.6)
1 (1.3)
2 (1.5)
4 (3.1)
5 (3.1)
5 (3.1)
2 (3.0)
4 (5.6)
Detected in urine only
40 (10.9)
34 (9.2)
12 (15.4)
9 (11.7)
12 (9.2)
12 (9.2)
16 (10.0)
13 (8.1)
4 (6.1)
8 (11.3)
Detected in serum free light chains only
29 (7.9)
28 (7.6)
7 (9.0)
4 (5.2)
11 (8.5)
12 (9.2)
11 (6.9)
12 (7.5)
6 (9.1)
8 (11.3)
Cytogenetic profile, n (%)§
(n=319)
(n=323)
(n=66)
(n=66)
(n=112)
(n=119)
(n=141)
(n=138)
(n=57)
(n=60)
Standard risk
271 (85.0)
279 (86.4)
56 (84.8)
58 (87.9)
98 (87.5)
103 (86.6)
117 (83.0)
118 (85.5)
47 (82.5)
52 (86.7)
High risk
48 (15.0)
44 (13.6)
10 (15.2)
8 (12.1)
14 (12.5)
16 (13.4)
24 (17.0)
20 (14.5)
10 (17.5)
8 (13.3)
Median time since initial diagnosis of MM, months (range)
0.95 (0.1-13.3)
0.89 (0-14.5)
0.85 (0.2-6.2)
0.82 (0.3-14.5)
0.90 (0.1-8.7)
0.95 (0.2-9.2)
0.95 (0.2-13.3)
0.92 (0.0-9.2)
1.02 (0.2-13.3)
0.95 (0.0-9.2)
*ECOG PS is scored on a scale of 0 to 5, with 0 indicating no symptoms and higher scores indicating increasing disability.
†ISS disease stage was based on the combination of serum β2-microglobulin and albumin.
‡Includes IgD, IgM, IgE, and biclonal.
§Cytogenetic risk was assessed by fluorescence in situ hybridization or karyotype testing; high risk was defined as the presence of t(4;14), t(14;16), or del(17p).
PFS with DRd and Rd for subgroups of patients aged <70 years, ≥70 to <75 years, and ≥75 years5
PFS with DRd and Rd for subgroups of patients aged >80 years5
Response rates by age subgroup in the ITT population5
MRD-negativity (10-5) rates by age subgroup in the ITT population5
After 28 months of follow-up:
Serious adverse reactions with a 2% greater incidence in the DRd arm compared to the Rd arm were1:
Pneumonia (DRd 15% vs Rd 8%)
Bronchitis (DRd 4% vs Rd 2%)
Dehydration (DRd 2% vs Rd <1%)
Adverse reactions reported in ≥10% of patients and with at least a 5% greater frequency in the DRd arm in MAIA1
Adverse reaction
DRd (n=364)
Rd (n=365)
All grades (%)
Grade 3 (%)
Grade 4 (%)
All grades (%)
Grade 3 (%)
Grade 4 (%)
Gastrointestinal disorders
Diarrhea
57
7
0
46
4
0
Constipation
41
1
<1
36
<1
0
Nausea
32
1
0
23
1
0
Vomiting
17
1
0
12
<1
0
Infections
Upper respiratory tract infection*
52
2
<1
36
2
<1
Bronchitis†
29
3
0
21
1
0
Pneumonia‡
26
14
1
14
7
1
Urinary tract infection
18
2
0
10
2
0
General disorders and administration site conditions
This analysis is not included in the Prescribing Information. This analysis was not adjusted for multiple comparisons, and no conclusions should be drawn.
Summary of any grade (≥30%) and Grade 3/4 (≥20%) TEAEs in the safety population5
DRd (n=364)
Rd (n=365)
Any grade
Grade 3/4
Any grade
Grade 3/4
Hematologic, n (%)
Neutropenia
224 (61.5)
197 (54.1)
166 (45.5)
135 (37.0)
Anemia
154 (42.3)
62(17.0)
150 (41.1)
79 (21.6)
Non-hematologic, n (%)
Diarrhea
240 (65.9)
33 (9.1)
188 (51.5)
22 (6.0)
Fatigue
164 (45.1)
33 (9.1)
114 (31.2)
17 (4.7)
Constipation
157 (43.1)
6 (1.6)
137 (37.5)
2 (0.5)
Peripheral edema
155 (42.6)
10 (2.7)
117 (32.1)
3 (0.8)
Back pain
155 (42.6)
14 (3.8)
109 (29.9)
14 (3.8)
Asthenia
136 (37.4)
19 (5.2)
101 (27.7)
18 (4.9)
Nausea
133 (36.5)
7 (1.9)
88 (24.1)
2 (0.5)
Insomnia
125 (34.3)
11 (3.0)
116 (31.8)
14 (3.8)
Bronchitis
124 (34.1)
12 (3.3)
87 (23.8)
7 (1.9)
Pneumonia
113 (31.0)
71 (19.5)
66 (18.1)
39 (10.7)
Cough
123 (33.8)
2 (0.5)
65 (17.8)
0
Dyspnea
119 (32.7)
12 (3.3)
63 (17.3)
4 (1.1)
Weight decreased
112 (30.8)
10 (2.7)
69 (18.9)
11 (3.0)
Muscle spasms
111 (30.5)
2 (0.5)
86 (23.6)
5 (1.4)
Peripheral sensory neuropathy
111 (30.5)
9 (2.5)
66 (18.1)
2 (0.5)
This analysis is not included in the Prescribing Information. This analysis was not adjusted for multiple comparisons, and no conclusions should be drawn.
Summary of death and causes of death in the safety population11*
n (%)
DRd (n=364)
Rd (n=365)
Total number of patients who died during the study
173 (47.5)
218 (59.7)
Primary cause of death
Disease progression
76 (20.9)
88 (24.1)
AEs
44 (12.1)
40 (11.0)
Related to study treatment†
14 (3.8)
10 (2.7)
Unrelated to study treatment
28 (7.7)
29 (7.9)
Other ‡
53 (14.6)
90 (24.7)
Infections/infestations
9 (2.5)
30 (8.2)
General disorders/administration site conditions§
11 (3.0)
5 (1.4)
Neoplasms (benign, malignant, or unspecified)
11 (3.0)
4 (1.1)
Cardiac disorders
1 (0.3)
8 (2.2)
Nervous system disorders
3 (0.8)
5 (1.4)
Unknown
13 (3.6)
27 (7.4)
Deaths within 30 days of last study treatment dose
31 (8.5)
35 (9.6)
Primary cause of death
Disease progression
1 (0.3)
1 (0.3)
AEs
29 (8.0)
32 (8.8)
Related to study treatment†
11 (3.0)
10 (2.7)
Unrelated to study treatment
18 (4.9)
22 (6.0)
Other‖
1 (0.3)
2 (0.5)
*The safety population included all randomized patients who received ≥1 dose of study treatment. †AEs were related to ≥1 of the 3 components of study treatment: daratumumab, lenalidomide, and dexamethasone. ‡Other reasons were reported in ≥1% of patients in either treatment group. §All events were related to the general health condition of the patient. ‖Includes a nervous system disorder in 1 patient in the DRd group and a blood and lymphatic system disorder and general disorder/administration site condition in 1 patient each in the Rd group.
These analyses are not included in the Prescribing Information for DARZALEX®. These analyses were conducted post hoc, and there are insufficient numbers of patients per subgroup to make definitive conclusions of safety among the subgroups.
After 64.5 months of follow-up:
Rates of Grade 3/4 TEAEs were generally higher in frail vs non-frail patients
COVID-19 infections/pneumonia were reported in <2% of patients in the DRd arm across subgroups
There were no new safety signals beyond the typical neutropenia and infection TEAEs occurring with DRd
The incidence of TEAEs leading to study treatment discontinuation was slightly lower in the DRd arm across frailty subgroups
The incidence of related serious TEAEs was similar in those receiving DRd compared with Rd across most frailty subgroups
Grade 3/4 TEAEs and treatment-related discontinuations
n (%)
Non-frail
Frail
DRd (n=196)
Rd (n=199)
DRd (n=168)
Rd (n=166)
Any Grade 3/4 TEAE
188 (95.9)
172 (86.4)
161 (95.8)
152 (91.6)
Neutropenia
96 (49.0)
79 (39.7)
101 (60.1)
56 (33.7)
Infections & infestations SOC
77 (39.3)
55 (27.6)
78 (46.4)
53 (31.9)
TEAE leading to study treatment discontinuation
26 (13.3)
47 (23.6)
27 (16.1)
40 (24.1)
Causes of death
n (%)
Non-frail
Frail
DRd (n=196)
Rd (n=199)
DRd (n=168)
Rd (n=166)
TEAE
7 (3.6)
10 (5.0)
22 (13.1)
21 (12.7)
Progressive disease
26 (13.3)
40 (20.1)
30 (17.9)
29 (17.5)
After 64.5 months of follow-up:
Grade 3/4 TEAEs occurred in 95.5% of patients in the DRd arm vs 95.0% in the Rd arm who were ≥75 years of age and 92.3% and 95.7%, respectively, in those ≥80 years of age
Safety profile in patients ≥75 years of age
Serious TEAEs occurred in 80.9% of patients in the DRd arm and 79.2% in the Rd arm, with pneumonia being the most common (19.7% and 12.6%, respectively)
TEAEs that led to treatment discontinuation occurred in 15.3% of patients in the DRd arm and 27.7% in the Rd arm
TEAEs with an outcome of death occurred in 11.5% of patients in the DRd arm and 13.2% in the Rd arm
Safety profile in patients ≥80 years of age
Serious TEAEs occurred in 81.5% of patients in the DRd arm and 82.9% in the Rd arm, with pneumonia being the most common (24.6% and 8.6%, respectively)
TEAEs that led to treatment discontinuation occurred in 6.2% of patients in the DRd arm and 20.0% in the Rd arm
TEAEs with an outcome of death occurred in 12.3% of patients in the DRd arm and 11.4% in the Rd arm
Most common any grade or Grade 3/4 TEAEs among patients aged ≥75 years and ≥80 years in the safety population10*
TEAE, n(%)
≥75 years
≥80 years
DRd (n=157)
Rd (n=159)
DRd (n=65)
Rd (n=70)
Any grade
Grade 3/4
Any grade
Grade 3/4
Any grade
Grade 3/4
Any grade
Grade 3/4
Hematologic
Neutropenia
109 (69.4)
98 (62.4)
81 (50.9)
66 (41.5)
45 (69.2)
37 (56.9)
34 (48.6)
26 (37.1)
Anemia
71 (45.2)
32 (20.4)
73 (45.9)
40 (25.2)
31 (47.7)
12 (18.5)
35 (50.0)
19 (27.1)
Thrombocytopenia
39 (24.8)
16 (10.2)
43 (27.0)
19 (11.9)
21 (32.3)
7 (10.8)
20 (28.6)
8 (11.4)
Lymphopenia
37 (23.6)
33 (21.0)
25 (15.7)
20 (12.6)
10 (15.4)
8 (12.3)
13 (18.6)
10 (14.3)
Non-hematologic
Diarrhea
98 (62.4)
16 (10.2)
80 (50.3)
8 (5.0)
37 (56.9)
5 (7.7)
35 (50.0)
3 (4.3)
Peripheral edema
76 (48.4)
6 (3.8)
53 (33.3)
2 (1.3)
31 (47.7)
0
24 (34.3)
2 (2.9)
Constipation
75 (47.8)
2 (1.3)
61 (38.4)
1 (0.6)
27 (41.5)
0
27 (38.6)
1 (1.4)
Fatigue
73 (46.5)
15 (9.6)
48 (30.2)
8 (5.0)
26 (40.0)
7 (10.8)
19 (27.1)
3 (4.3)
Back pain
65 (41.4)
7 (4.5)
53 (33.3)
6 (3.8)
24 (36.9)
2 (3.1)
21 (30.0)
2 (2.9)
Asthenia
58 (36.9)
8 (5.1)
43 (27.0)
10 (6.3)
25 (38.5)
3 (4.6)
26 (37.1)
8 (11.4)
Weight decreased
49 (31.2)
6 (3.8)
31 (19.5)
5 (3.1)
19 (29.2)
2 (3.1)
16 (22.9)
2 (2.9)
Bronchitis
48 (30.6)
7 (4.5)
31 (19.5)
4 (2.5)
18 (27.7)
2 (3.1)
15 (21.4)
1 (1.4)
Nausea
48 (30.6)
2 (1.3)
40 (25.2)
0
21 (32.3)
1 (1.5)
20 (28.6)
0
Pneumonia
44 (28.0)
32 (20.4)
33 (20.8)
23 (14.5)
22 (33.8)
17 (26.2)
13 (18.6)
8 (11.4)
Pyrexia
44 (28.0)
6 (3.8)
22 (13.8)
3 (1.9)
20 (30.8)
4 (6.2)
7 (10.0)
0
*Any grade TEAEs and Grade 3/4 TEAEs listed are those that occurred in ≥30% and ≥20% of patients in either group, respectively.
Contraindications1:
DARZALEX® is contraindicated in patients with a history of severe hypersensitivity (e.g. anaphylactic reactions) to daratumumab or any of the components of the formulation.
DARZALEX® can cause severe and/or serious infusion-related reactions including anaphylactic reactions
These reactions can be life-threatening, and fatal outcomes have been reported
In clinical trials (monotherapy and combination: N=2,066), infusion-related reactions occurred in 37% of patients with the Week 1 (16 mg/kg) infusion, 2% with the Week 2 infusion, and cumulatively 6% with subsequent infusions
Less than 1% of patients had a Grade 3/4 infusion-related reaction at Week 2 or subsequent infusions
The median time to onset was 1.5 hours (range: 0 to 73 hours)
Nearly all reactions occurred during infusion or within 4 hours of completing DARZALEX®
Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, hypertension, tachycardia, headache, laryngeal edema, pulmonary edema, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma
Signs and symptoms may include respiratory symptoms, such as nasal congestion, cough, throat irritation, as well as chills, vomiting and nausea. Less common signs and symptoms were wheezing, allergic rhinitis, pyrexia, chest discomfort, pruritus, hypotension, and blurred vision
When DARZALEX® dosing was interrupted in the setting of ASCT (CASSIOPEIA) for a median of 3.75 months (range: 2.4 to 6.9 months), upon re-initiation of DARZALEX®, the incidence of infusion-related reactions was 11% for the first infusion following ASCT
Infusion rate/dilution volume used upon re-initiation was that used for the last DARZALEX® infusion prior to interruption for ASCT. Infusion-related reactions occurring at re-initiation of DARZALEX® following ASCT were consistent in terms of symptoms and severity (Grade 3 or 4: <1%) with those reported in previous studies at Week 2 or subsequent infusions
In EQUUELUS, patients receiving combination treatment (n=97) were administered the first 16 mg/kg dose at Week 1 split over two days i.e. 8 mg/kg on Day 1 and Day 2, respectively
The incidence of any grade infusion-related reactions was 42%, with 36% of patients experiencing infusion-related reactions on Day 1 of Week 1, 4% on Day 2 of Week 1, and 8% with subsequent infusions
Pre-medicate patients with antihistamines, antipyretics and corticosteroids
Frequently monitor patients during the entire infusion
Interrupt DARZALEX® infusion for reactions of any severity and institute medical management as needed
Permanently discontinue DARZALEX® therapy if an anaphylactic reaction or life-threatening (Grade 4) reaction occurs and institute appropriate emergency care
For patients with Grade 1, 2, or 3 reactions, reduce the infusion rate when re-starting the infusion
To reduce the risk of delayed infusion-related reactions, administer oral corticosteroids to all patients following DARZALEX® infusions
Patients with a history of chronic obstructive pulmonary disease may require additional post-infusion medications to manage respiratory complications
Consider prescribing short- and long-acting bronchodilators and inhaled corticosteroids for patients with chronic obstructive pulmonary disease
Ocular adverse reactions, including acute myopia and narrowing of the anterior chamber angle due to ciliochoroidal effusions with potential for increased intraocular pressure or glaucoma, have occurred with DARZALEX® infusion
If ocular symptoms occur, interrupt DARZALEX® infusion and seek immediate ophthalmologic evaluation prior to restarting DARZALEX®
Infections
DARZALEX® can cause serious, life-threatening, or fatal infections. In patients who received DARZALEX® in a pooled safety population (N=2066), serious infections, including opportunistic infections, occurred in 22.6% of patients, Grade 3 or 4 infections occurred in 24.3%, and fatal infections occurred in 1.2%
The most common (≥2%) types of serious infection reported were pneumonia (11%), upper respiratory tract infection (4%), sepsis (3%), and bronchitis (2%)
Monitor patients for signs and symptoms of infection prior to and during treatment with DARZALEX® and treat appropriately. Administer prophylactic antimicrobials according to guidelines
Interference with serological testing
Daratumumab binds to CD38 on RBCs and results in a positive Indirect Antiglobulin Test (Indirect Coombs test)
Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab infusion
Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient’s serum
The determination of a patient’s ABO and Rh blood type are not impacted
Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX®
Type and screen patients prior to starting DARZALEX®
Neutropenia and thrombocytopenia
DARZALEX® may increase neutropenia and thrombocytopenia induced by background therapy
Monitor complete blood cell counts periodically during treatment according to manufacturer’s prescribing information for background therapies
Monitor patients with neutropenia for signs of infection
Consider withholding DARZALEX® until recovery of neutrophils or for recovery of platelets
Interference with determination of complete response
Daratumumab is a human IgG kappa monoclonal antibody that can be detected on both, the serum protein electrophoresis and immunofixation assays used for the clinical monitoring of endogenous M‑protein
This interference can impact the determination of complete response and of disease progression in some patients with IgG kappa myeloma protein
Embryo-fetal toxicity
Based on the mechanism of action, DARZALEX® can cause fetal harm when administered to a pregnant woman
DARZALEX® may cause depletion of fetal immune cells and decreased bone density
Advise pregnant women of the potential risk to a fetus
Advise females with reproductive potential to use effective contraception during treatment with DARZALEX® and for 3 months after the last dose
The combination of DARZALEX® with lenalidomide, pomalidomide, or thalidomide is contraindicated in pregnant women, because lenalidomide, pomalidomide, and thalidomide may cause birth defects and death of the unborn child
Refer to the lenalidomide, pomalidomide, or thalidomide Prescribing Information on use during pregnancy
Adverse reactions
The most frequently reported adverse reactions (incidence ≥20%) were upper respiratory infection, neutropenia, infusion-related reactions, thrombocytopenia, diarrhea, constipation, anemia, peripheral sensory neuropathy, fatigue, peripheral edema, nausea, cough, pyrexia, dyspnea, and asthenia
The most common hematologic laboratory abnormalities (≥40%) with DARZALEX® are neutropenia, lymphopenia, thrombocytopenia, leukopenia, and anemia
DARZALEX® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104-2115.
Supplement to: Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104-2115.
Facon T, Moreau P, Weisel K, et al. Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025;39(4):942-950.
Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582-1596.
Facon T, Kumar SK, Orlowski RZ, et al. Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis. Leukemia. 2026. doi:10.1038/s41375-026-03097-9.
Venner CP, Zweegman S, Kumar SK, et al. Age and frailty analyses of transplant-ineligible patients with newly diagnosed multiple myeloma in the phase 3 MAIA and CEPHEUS trails of daratumumab + lenalidomide-dexamethasone and bortezomib + lenalidomide-dexamethasone. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2026; Chicago, IL.
Larocca A, Marenchino D, Varettoni M, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34(1):224-233.
Facon T, Kumar SK, Orlowski R, et al. Final survival analysis of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: MAIA study. Poster presented at: The European Hematology Association (EHA) Hybrid Congress; June 13-16, 2024; Madrid, Spain.
ABO
ABO blood group system
NDMM
Newly diagnosed multiple myeloma
AE
Adverse event
NE
Not estimable
ASCT
Autologous stem cell transplant
NGS
Next-generation sequencing
BMI
Body mass index
NR
Not reached
CCI
Charlson comorbidity index
OR
Odds ratio
CD38
Cluster of differentiation 38
ORR
Overall response rate
CI
Confidence interval
OS
Overall survival
COVID-19
Coronavirus disease 2019
PD
Progressive disease
CR
Complete response
PFS
Progression-free survival
CrCl
Creatinine clearance
PO
Oral
D
Daratumumab
PR
Partial response
d
Dexamethasone
Q2W
Every 2 weeks
DRd
Daratumumab + lenalidomide + dexamethasone
Q4W
Every 4 weeks
ECOG PS
Eastern Cooperative Oncology Group performance status